Research Article

You have full text access to this OnlineOpen article

Influence of inflammatory polyarthritis on cancer incidence and survival: Results from a community-based prospective study

  1. Jarrod Franklin1,
  2. Mark Lunt1,
  3. Diane Bunn2,
  4. Deborah Symmons1,
  5. Alan Silman1,*

Article first published online: 27 FEB 2007

DOI: 10.1002/art.22430

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 56, Issue 3, pages 790–798, March 2007

Additional Information

How to Cite

Franklin, J., Lunt, M., Bunn, D., Symmons, D. and Silman, A. (2007), Influence of inflammatory polyarthritis on cancer incidence and survival: Results from a community-based prospective study. Arthritis & Rheumatism, 56: 790–798. doi: 10.1002/art.22430

Author Information

  1. 1

    University of Manchester, Manchester, UK

  2. 2

    Norfolk Arthritis Register, Norfolk, and Norwich Hospital, Norwich, UK

*ARC Epidemiology Research Unit, Manchester University Medical School, Room 2.514 Stopford Building, Oxford Road, Manchester M13 9PT, UK

Publication History

  1. Issue published online: 27 FEB 2007
  2. Article first published online: 27 FEB 2007
  3. Manuscript Accepted: 28 NOV 2006
  4. Manuscript Received: 24 MAY 2006

Funded by

  • Bristol-Myers Squibb
  • Arthritis Research Campaign, UK

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (111K)

REFERENCES

  • 1
    Monson RR, Hall AP. Mortality among arthritics. J Chronic Dis 1976; 29: 459–67.
  • 2
    Allebeck P. Increased mortality in rheumatoid arthritis. Scand J Rheumatol 1982; 11: 81–6.
  • 3
    Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481–94.
    Direct Link:
  • 4
    Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002; 46: 2010–9.
    Direct Link:
  • 5
    Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998; 25: 1072–7.
  • 6
    Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 2004; 33: 221–7.
  • 7
    Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 2003; 30: 958–65.
  • 8
    Bjornadal L, Baecklund E, Yin L, Granath F, Klareskog L, Ekbom A. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964–95. J Rheumatol 2002; 29: 906–12.
  • 9
    Kvalvik AG, Jones MA, Symmons DP. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 2000; 29: 29–37.
  • 10
    Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978; 31: 691–6.
  • 11
    Baltus JA, Boersma JW, Hartman AP, Vandenbroucke JP. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis 1983; 42: 368–73.
  • 12
    Prior P. Cancer and rheumatoid arthritis: epidemiologic considerations. Am J Med 1985; 78: 15–21.
  • 13
    Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988; 47: 988–92.
  • 14
    Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB, for the Rheumatoid Arthritis Azathioprine Registry Steering Committee. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. J Rheumatol 1991; 18: 809–14.
  • 15
    Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996; 32A: 1753–7.
  • 16
    Ekstrom K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003; 48: 963–70.
    Direct Link:
  • 17
    Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Incidence of lymphoma in a large primary care derived cohort of inflammatory polyarthritis. Ann Rheum Dis 2006; 65: 617–22.
  • 18
    Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307–11.
  • 19
    Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti–tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740–51.
    Direct Link:
  • 20
    Katusic S, Beard CM, Kurland LT, Weis JW, Bergstralh E. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 1985; 78: 50–5.
  • 21
    Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000; 88: 497–502.
    Direct Link:
  • 22
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
    Direct Link:
  • 23
    Wiles N, Symmons DP, Harrison B, Barrett E, Barrett JH, Scott DG, et al. Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum 1999; 42: 1339–46.
    Direct Link:
  • 24
    Symmons DP, Silman AJ. The Norfolk Arthritis Register (NOAR) [review]. Clin Exp Rheumatol 2003; 21(5 Suppl 31 ): S94–9.
  • 25
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–45.
    Direct Link:
  • 26
    Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: results from a primary care-based inception cohort of patients. Rheumatology (Oxford) 2002; 41: 246–52.
  • 27
    Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 2002; 16: 707–22.
  • 28
    MacGregor AJ, Bamber S, Silman AJ. A comparison of the performance of different methods of disease classification for rheumatoid arthritis: results of an analysis from a nationwide twin study. J Rheumatol 1994; 21: 1420–6.
  • 29
    Clark TG, Murphy MF, Hey K, Drury M, Cheng KK, Aveyard P. Does smoking influence survival in cancer patients through effects on respiratory and vascular disease? Eur J Cancer Prev 2006; 15: 87–90.
  • 30
    Askling J, Fored M, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumor necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1414–20.
  • 31
    Watson KD, Dixon WG, Hyrich KL, Lunt M, Symmons DP, Silman AJ. Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis: results from the BSR Biologics Register. Rheumatology (Oxford) 2006; 45 Suppl 1: i10.
  • 32
    Ledingham J, Deighton C, for the British Society for Rheumatology Standards, Guidelines and Audit Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005; 44: 157–63.
View Full Article (HTML) Get PDF (111K)